ALPS Medical Breakthroughs ETF (SBIO) Fund Overview
Educational signal · not a buy or sell recommendation · How to read this
Beta 1.34: the stock has moved about 34% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerALPS Medical Breakthroughs ETF (SBIO) trades at $56.15. The ALPS Medical Breakthroughs ETF (SBIO) aims to replicate the performance of the S-Network Medical Breakthroughs Index (PMBI). It focuses on companies with significant potential in the medical sector. Sector: Financials.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for SBIO: SBIO does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
ALPS Medical Breakthroughs ETF (SBIO) Financial Services Profile
ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund seeking to mirror the S-Network Medical Breakthroughs Index, targeting companies poised for innovation in the medical sector. With a focus on breakthrough potential, SBIO offers investors exposure to a dynamic segment within the broader healthcare landscape, albeit with inherent market risks.
What Is the Investment Thesis for SBIO?
SBIO presents an investment opportunity for those seeking exposure to the medical breakthroughs sector. With a market capitalization of $0.14 billion and a beta of 1.34, SBIO offers a potentially high-growth but also volatile investment. The fund's value is tied to the performance of the S-Network Medical Breakthroughs Index (PMBI), which focuses on companies with innovative medical technologies. A key growth catalyst is the ongoing advancements in medical science and technology, which could drive the performance of companies held within the ETF. However, potential risks include regulatory hurdles, clinical trial failures, and market volatility affecting the healthcare sector. Investors should monitor the performance of the PMBI and the financial health of the companies within the ETF to assess its long-term value.
Based on FMP financials and quantitative analysis
SBIO Key Highlights
Market Cap of $0.14B indicates a relatively small fund size, which can lead to higher volatility.
- Beta of 1.34 suggests that SBIO is more volatile than the overall market.
- The ETF tracks the S-Network Medical Breakthroughs Index (PMBI), providing exposure to companies with high innovation potential.
- SBIO offers targeted exposure to the medical breakthroughs sector, which can be beneficial for investors seeking diversification within the healthcare industry.
- The fund's performance is directly linked to the success of medical companies in developing and commercializing new technologies and treatments.
Who Are SBIO's Competitors?
SBIO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AFMC First Trust Active Factor Mid Cap ETF | $40.49 | +1.03% | $122M | — |
| CIL VictoryShares International Volatility Wtd ETF | $56.91 | +0.14% | $102M | — |
| EVX VanEck Environmental Services ETF | $39.09 | +1.60% | $97.8M | — |
| FITE State Street SPDR S&P Kensho Future Security ETF | $112.71 | +1.18% | $117M | — |
| IFGL iShares International Developed Real Estate ETF | $20.44 | -0.32% | $73.4M | — |
| BLK BlackRock, Inc. | $1059.63 | -0.44% | $164B | 51 5-pillar |
| BX Blackstone Inc. | $111.74 | -0.45% | $135B | 68 5-pillar |
| APOS Apollo Global Management, Inc. | $25.59 | -0.23% | $74.8B | 56 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SBIO's Key Strengths?
Targeted exposure to the high-growth medical breakthroughs sector.
- Diversified portfolio of innovative medical companies.
- Transparent and rules-based index methodology.
- Managed by an experienced ETF provider.
What Are SBIO's Weaknesses?
Relatively small market capitalization, leading to potential volatility.
- Concentration in the healthcare sector, increasing sector-specific risk.
- Dependence on the performance of the S-Network Medical Breakthroughs Index (PMBI).
- Subject to regulatory and clinical trial risks.
What Are the Key Risks for SBIO?
Regulatory setbacks and delays in approvals.
- Clinical trial failures and negative data releases.
- Market volatility and economic downturns affecting the healthcare sector.
- Competition from other healthcare and biotechnology companies.
- Patent protection and intellectual property disputes.
What Are SBIO's Competitive Advantages?
- First-mover advantage in offering a dedicated ETF focused on medical breakthroughs.
- Brand recognition and reputation of ALPS Advisors, Inc.
- Proprietary index methodology for selecting companies with breakthrough potential.
What Does SBIO Do?
The ALPS Medical Breakthroughs ETF (SBIO) is designed to provide investment results that closely correspond, before fees and expenses, to the performance of the S-Network Medical Breakthroughs Index (PMBI). This index focuses on identifying and tracking companies within the medical sector that are demonstrating significant breakthrough potential. The ETF serves as a vehicle for investors seeking exposure to innovative companies that are developing and commercializing new medical technologies, treatments, and therapies. SBIO's underlying index uses a rules-based methodology to select companies, aiming to capture those with the highest potential for growth and innovation. The ETF's investment strategy involves holding a portfolio of stocks that mirrors the composition of the PMBI, thereby providing investors with diversified exposure to the medical breakthroughs sector. SBIO does not have a founding story in the traditional sense of a company, as it is an ETF created and managed by ALPS Advisors, Inc. to track a specific index. Its evolution is tied to the performance and composition of the S-Network Medical Breakthroughs Index. The ETF's geographic reach is global, as it can invest in companies listed on various exchanges worldwide, provided they meet the index's selection criteria.
What Products and Services Does SBIO Offer?
- Tracks the performance of the S-Network Medical Breakthroughs Index (PMBI).
- Invests in companies with significant breakthrough potential in the medical sector.
- Provides investors with exposure to innovative medical technologies, treatments, and therapies.
- Offers a diversified portfolio of stocks within the medical breakthroughs sector.
- Seeks to replicate the returns of the PMBI before fees and expenses.
- Manages a portfolio of stocks that mirrors the composition of the PMBI.
How Does SBIO Make Money?
- Generates revenue through management fees charged to investors.
- Aims to provide investment results that correspond to the performance of the S-Network Medical Breakthroughs Index (PMBI).
- Offers a vehicle for investors seeking exposure to innovative companies in the medical sector.
What Industry Does SBIO Operate In?
The asset management industry is characterized by intense competition and evolving investor preferences. ETFs like SBIO compete with other healthcare and biotechnology-focused funds, as well as broader market index funds. The medical breakthroughs sector is driven by innovation, regulatory approvals, and market demand for new treatments. The industry is subject to regulatory scrutiny, clinical trial risks, and patent protection challenges. SBIO's success depends on its ability to accurately track the PMBI and provide investors with exposure to high-growth medical companies.
Who Are SBIO's Key Customers?
- Retail investors seeking exposure to the medical breakthroughs sector.
- Institutional investors looking for diversified healthcare investments.
- Financial advisors seeking to provide clients with access to innovative medical companies.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
- ● This is an etf, not an operating company
SBIO Financials
Bull Case vs Bear Case
Bull Case
- Targeted exposure to the high-growth medical breakthroughs sector.
- Diversified portfolio of innovative medical companies.
- Transparent and rules-based index methodology.
- Managed by an experienced ETF provider.
Bear Case
- Relatively small market capitalization, leading to potential volatility.
- Concentration in the healthcare sector, increasing sector-specific risk.
- Dependence on the performance of the S-Network Medical Breakthroughs Index (PMBI).
- Subject to regulatory and clinical trial risks.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SBIO Latest News
No recent news available for SBIO.
SBIO Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for SBIO.
Price Targets
Wall Street price target analysis for SBIO.
SBIO MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for SBIO; grades run from A+ (80-100) to F (below 30).
ALPS Medical Breakthroughs ETF Financials Stock: Key Questions Answered
How does ALPS Medical Breakthroughs ETF generate revenue in the financial services sector?
As an exchange-traded fund (ETF), ALPS Medical Breakthroughs ETF (SBIO) generates revenue primarily through management fees. These fees are charged to investors as a percentage of the assets under management (AUM).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- The information provided is based on publicly available data and may be subject to change.
- Investment decisions should be based on individual risk tolerance and financial circumstances.